RecruitingNot ApplicableNCT06391814
Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)
Open-Label Individual Patient Study of Epstein-Barr Virus (EBV) Specific T-Cell Lines for the Treatment of a Lymphoproliferative Disease and Hemophagocytic Syndrome Associated With EBV
Sponsor
Ciusss de L'Est de l'Île de Montréal
Enrollment
1 participants
Start Date
Jan 16, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Single-patient trial aiming to provide immunological consolidation following allogeneic stem cell transplantation to a young adult patient suffering from a systemic EBV-positive lymphoma of childhood.
Eligibility
Sex: FEMALE
Inclusion Criteria3
- Capacity to provide informed consent
- Age ≥ 18
- Negative serum pregnancy test and use of effective contraception method.
Exclusion Criteria4
- Administration within less than 28 days of T-cell depleting antibodies (ATG, OKT3, Campath)
- Pregnancy
- Any abnormal condition or laboratory result that is considered by the Principal Investigator capable of altering patient or study outcome.
- Active uncontrolled GVHD (acute GVHD grade II-IV or progressive extensive chronic GVHD) at time of enrolment or infusion.
Interventions
BIOLOGICALEBV-specific T cells
Consolidative cellular immunotherapy consisting of one (or up to 4) infusion of ex vivo expanded T cells
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06391814